CCA
KPTI icon

Column Capital Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

Column Capital Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-21
Closed -$6K – 760
2019
Q4 		$6K Buy
+21
New +$4.56K ﹤0.01% 510

Other funds holding KPTI

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Column Capital Advisors's KPTI Position: Q1 2020 in Review

Column Capital Advisors sold out of Karyopharm Therapeutics (KPTI) in Q1 2020, closing a stake of 21 shares — an estimated $6K sold.

Column Capital Advisors first reported a position in KPTI in Q4 2019 and held it in 1 quarter. The position peaked at $6K in Q4 2019. 136 funds tracked by Wall St. Rank hold KPTI as of Q1 2020.

  • Column Capital Advisors reported no remaining Karyopharm Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Column Capital Advisors sold 21 Karyopharm Therapeutics shares in Q1 2020, an estimated $6K.
  • Column Capital Advisors first reported a position in Karyopharm Therapeutics in Q4 2019 and held it in 1 quarter.
  • Column Capital Advisors's Karyopharm Therapeutics position peaked at $6K in Q4 2019.
  • 136 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2020.

Based on Column Capital Advisors's 13F filing for Q1 2020, filed 11 May 2020.